Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: Evidence from a post-marketing surveillance study of 1467 patients

Clinical Drug Investigation

Volumn 24, Issue 8, 2004, Pages 441-448

  Koch, H ^a   Landen, H ^b   Stauch, K ^b  

^a Kreiskrankenhaus Beeskow ^*  (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CLAVULANIC ACID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENERAL PRACTICE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INNER EAR DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PARALYTIC ILEUS; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 4344565726     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424080-00002     Document Type: Article

References (47)

1. Lindbaek M, Berild D, Straand J, et al. Influence of prescription patterns in general practice on anti-microbial resistance in Norway. Br J Gen Pract 1999; 49: 436-40
2. Hoyert DL, Arias E, Smith BL, et al. Deaths: final data for 1999. [http: //www.cdc.gov/nchs/releases/01facts/99mortality.htm]. Natl Vital Stat Rep 2001; 49: 1-114
3. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-82
4. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
5. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37
6. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 Suppl. 5: S1-28
7. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4
8. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998; 55: 31-45
9. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330-5
10. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J 2002; 36 Suppl.: 20-7s
11. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents 1998; 10: 23-30
12. Weiss K, Laverdiere M, Restieri C. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 1998; 42: 523-5
13. Biedenbach DJ, Barrett MS, Croco MA, et al. BAY 12-8039, a novel fluoroquinolone: activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis 1998; 32: 45-50
14. Reinert RR, Schlaeger JJ, Lutticken R. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae. J Antimicrob Chemother 1998; 42: 803-6
15. Rubio MC, Goni P, Vergara Y, et al. Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents. J Chemother 1999; 11: 191-4
16. Barry AL, Fuchs PC, Brown SD. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Eur J Clin Microbiol Infect Dis 1999; 18: 305-9
17. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45-50
18. Wiedemann B. Pharmacodynamic activity of moxifloxacin in an in vitro model against Gram-positive and Gram-negative pathogens [abstract P773]. Clin Microbiol Infect 1999; 5 Suppl. 3: 292
19. Andrews J, Honeybourne D, Jevons G, et al. Penetration of Bay 12-8039 into bronchial mucosa, epithelial lining [abstract A29, page 9], 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1998 Sep 24-27; San Diego (CA)
20. Muller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9
21. Patel T, Pearl J, Williams J, et al. Efficacy and safety of ten day moxifloxacin 400mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respir Med 2000; 94: 97-105
22. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748-63
23. Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95: 553-64
24. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185-95
25. Iannini PB, Mandell LA. An updated safety profile of moxifloxacin. J Chemother 2002; 14 Suppl. 2: 29-34
26. Landen H, Moller M, Tillotson GS, et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29: 51-60
27. Landen H, Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia. Results of a postmarketing surveillance study. Clin Drug Invest 2001; 21: 801-11
28. Bauer T, Landen H, Stauch K. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis: comparison with prior macrolide treatment. Clin Drug Invest 2002; 22: 641-51
29. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-54
30. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-121
31. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052-9
32. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-24
33. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-9
34. Bell JM, Turnidge JD, Jones RN. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program (1998-1999), including an in vitro evaluation of BMS284756. Int J Antimicrob Agents 2002; 19: 125-32
35. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45: 1037-42
36. Felmingham D, Reinert RR. Prevalence of antibiotic resistance among European respiratory tract pathogens (1999/2000) [abstract, page 128]. Presentation No. 685, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001 Dec 16-19; Chicago (IL)
37. Reinert RR, Simic S, Al-Lahham A, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol 2001; 39: 1187-9
38. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-8
39. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11 Suppl. 1: 35-43
40. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999; 43 Suppl. B: 1-11
41. Jones ME, Staples AM, Critchley I, et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob Agents Chemother 2000; 44: 2645-52
42. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59: 115-39
43. Miravitlles M, Ros F, Cobos A, et al. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int J Clin Pract 2001; 55: 437-41
44. Burke T, Villanueva C, Mariano Jr H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther 1999; 21: 1664-77
45. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000; 94: 337-44
46. Rakkar S, Roberts K, Towe BF, et al. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001; 55: 309-15
47. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 13-59